Novartis new alliance.........................................

In early 40s to late 60s companies used to focus on antibacterial and antibiotics then 70's came the diabetics drugs then 80s and 90s was the era of AIDS drugs, early 2000 HINI drugs and now the focus is on New MAbs and Biopharma drugs for cancer therapy, Most of the top 10 companies in the world are spending around 15 to 20 % of there allocated research grants into cancer therapy. As estimated in some reports this segment is growing at the rate of 34% annually. After Pfizer and GSK's strategic mergers and agreements today Novratis has announced that it has entered into agreement with Forma Therapeutics (Headquarter in Cambridge and operations in North America and Asia), this deal will help Novartis to use Forma's expertise in cell based screening technology and chemistry based drug development. Already Forma has long time relation with Novartis as Novartis Option Fund has already invested around $4 million in March of 2008 on the later.